Medicine and Dentistry
Immune Checkpoint Inhibitor
75%
Overall Survival
75%
Cancer Treatment
50%
Immunotherapy
50%
Non Small Cell Lung Cancer
46%
Multiple Myeloma
25%
Mucositis
25%
Melphalan
25%
Computed Tomography Angiography
25%
Low Drug Dose
25%
Clinical Feature
25%
Oral Mucositis
25%
Computer Assisted Tomography
25%
Cohort Analysis
25%
Selection Bias
25%
Chronic Pancreatitis
25%
Health Care Cost
25%
Mucosa
25%
Drug Megadose
25%
Gene Expression
25%
Inflammatory Bowel Disease
25%
Liver Metastasis
24%
Lung Cancer
20%
Bone Metastasis
17%
Randomized Controlled Trial
15%
Cancer Registry
14%
Ulcerative Colitis
12%
Biopsy
12%
HLA-DRB1
12%
Proportional Hazards Model
12%
Biological Marker
11%
Crohn's Disease
10%
Scoring System
10%
Quantitative Imaging
10%
Pancreatic Duct
10%
Time to Treatment
10%
Progression Free Survival
10%
Cancer
8%
Prevalence
8%
Epidermal Growth Factor Receptor
7%
Anticarcinogen
7%
Prognostic Factor
7%
Electronic Health Record
7%
Long Term Survival
7%
Anaplastic Lymphoma Kinase
7%
Survival Rate
7%
Pancreas Cancer
6%
Malignant Neoplasm
6%
Oral Mucosa
6%
Dendritic Cell
6%
Keyphrases
Limits of Agreement
34%
Denmark
29%
Contrast-enhanced CT
25%
Point Process
25%
CT Angiography
25%
Subsequent Line
25%
Pretreated Patients
25%
Pyramidal Cells
25%
Survival Benefit
25%
Structured Space
25%
Abdominal Aortic Diameter
25%
Ecological Analysis
25%
Geographical Analysis
25%
Multi-observer
25%
Immune Checkpoint Inhibitors
25%
Ultra-low Dose
25%
Systemic Anti-cancer Therapy
25%
Potential Identification
25%
Serum Vitamin D Deficiency
25%
Bland-Altman Plot
25%
Multiple Observer
25%
Pharmaceutical Expenditure
25%
Multiple Myeloma
25%
Urbanization Impacts
25%
Linear Network
25%
Overall Survival
20%
Hierarchical Point Processes
16%
High-cost Patients
16%
Preapproval
16%
Lung Cancer Registry
16%
Time to Treatment Discontinuation
12%
HLA-DRB5
12%
Confidence Interval
10%
Spine Geometry
10%
Advanced Pancreatic Ductal Adenocarcinoma
10%
Geographical Distribution
9%
Self-correcting Process
8%
Thinning Algorithm
8%
Nonlinear Hawkes Process
8%
Conditional Intensity Function
8%
Performance Status
8%
Treatment Information
8%
Minicolumn Hypothesis
8%
Post-approval Changes
8%
Non-small Cell Lung Cancer (NSCLC)
8%
Liver Metastasis
8%
Multiple Measurements
7%
Rural Areas
6%
Environmental Exposure
6%
National Incidence
6%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Immune Checkpoint Inhibitor
75%
Pancreas Cancer
50%
Immunotherapy
50%
Non Small Cell Lung Cancer
46%
Lung Cancer
39%
Prostate Cancer
25%
Vitamin D
25%
Hypovitaminosis D
25%
Vitamin D Deficiency
25%
Clinical Feature
25%
Malignant Neoplasm
25%
Biological Marker
25%
Liver Metastasis
24%
Bone Metastasis
17%
Pancreas Adenocarcinoma
16%
Randomized Controlled Trial
15%
Cancer Registry
14%
HLA DRB5 Antigen
12%
HLA DRB1 Antigen
12%
Progression Free Survival
10%
Comorbidity
10%
Long Term Survival
7%
Anticarcinogen
7%
Anaplastic Lymphoma Kinase
7%
Survival Rate
7%
Epidermal Growth Factor Receptor
7%
Survival Factor
5%
Pembrolizumab
5%
Nivolumab
5%
